R oche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

Genentech's Portal study shows Susvimo maintains vision and retinal drying in wet AMD patients over five years with biannual ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the ...

Genentech is committed to helping people access the medicines they are prescribed and offers comprehensive services for people prescribed Susvimo to help minimize barriers to access and reimbursement.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo ® (ranibizumab injection) 100 ...

Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration has approved Susvimo ® 100 mg/mL for the treatment of diabetic retinopathy, a potentially ...

Genentech is reintroducing Susvimo ® (ranibizumab), a refillable ocular implant for the treatment of neovascular (wet) age-related macular degeneration (AMD), following the end of a voluntary recall.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the reintroduction of Susvimo ® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new two-year data from its Phase III studies of Vabysmo™ (fa ...

Genentech, a member of the Roche Group, announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo ® 100 mg/mL for the treatment of diabetic macular edema and ...

FDA Approves Genentech’s Susvimo for Diabetic Retinopathy May 22, 2025 11:45 AM ET Roche Holding AG (RHHBY) ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) 100 mg/mL for ...